scholarly journals Commentary on human pluripotent stem cell-based blood–brain barrier models

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Ethan S. Lippmann ◽  
Samira M. Azarin ◽  
Sean P. Palecek ◽  
Eric V. Shusta

Abstract In 2012, we provided the first published evidence that human pluripotent stem cells could be differentiated to cells exhibiting markers and phenotypes characteristic of the blood–brain barrier (BBB). In the ensuing years, the initial protocols have been refined, and the research community has identified both positive and negative attributes of this stem cell-based BBB model system. Here, we give our perspective on the current status of these models and their use in the BBB community, as well as highlight key attributes that would benefit from improvement moving forward.

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1294
Author(s):  
Yogesh R. Suryawanshi ◽  
Autumn J. Schulze

Glioblastoma is one of the most difficult tumor types to treat with conventional therapy options like tumor debulking and chemo- and radiotherapy. Immunotherapeutic agents like oncolytic viruses, immune checkpoint inhibitors, and chimeric antigen receptor T cells have revolutionized cancer therapy, but their success in glioblastoma remains limited and further optimization of immunotherapies is needed. Several oncolytic viruses have demonstrated the ability to infect tumors and trigger anti-tumor immune responses in malignant glioma patients. Leading the pack, oncolytic herpesvirus, first in its class, awaits an approval for treating malignant glioma from MHLW, the federal authority of Japan. Nevertheless, some major hurdles like the blood–brain barrier, the immunosuppressive tumor microenvironment, and tumor heterogeneity can engender suboptimal efficacy in malignant glioma. In this review, we discuss the current status of malignant glioma therapies with a focus on oncolytic viruses in clinical trials. Furthermore, we discuss the obstacles faced by oncolytic viruses in malignant glioma patients and strategies that are being used to overcome these limitations to (1) optimize delivery of oncolytic viruses beyond the blood–brain barrier; (2) trigger inflammatory immune responses in and around tumors; and (3) use multimodal therapies in combination to tackle tumor heterogeneity, with an end goal of optimizing the therapeutic outcome of oncolytic virotherapy.


1984 ◽  
Vol 436 (1 Multiple Scle) ◽  
pp. 52-67 ◽  
Author(s):  
WALLACE W. TOURTELLOTTE ◽  
MICHAEL J. WALSH ◽  
ROBERT W. BAUMHEFNER ◽  
SUSAN M. STAUGAITIS ◽  
PAUL SHAPSHAK

2013 ◽  
Vol 10 (1) ◽  
pp. 2 ◽  
Author(s):  
Ethan S Lippmann ◽  
Abraham Al-Ahmad ◽  
Sean P Palecek ◽  
Eric V Shusta

2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Ethan S. Lippmann ◽  
Abraham Al-Ahmad ◽  
Samira M. Azarin ◽  
Sean P. Palecek ◽  
Eric V. Shusta

Sign in / Sign up

Export Citation Format

Share Document